Deutsche Bank AG reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a report released on Tuesday. The firm currently has a GBX 6,200 ($76.73) price objective on the biopharmaceutical company’s stock.
AZN has been the subject of a number of other research reports. Jefferies Group raised their target price on shares of AstraZeneca plc from GBX 3,900 ($48.27) to GBX 4,100 ($50.74) and gave the company a hold rating in a research note on Tuesday, June 14th. BNP Paribas downgraded shares of AstraZeneca plc to a neutral rating and set a GBX 5,200 ($64.36) target price for the company. in a research note on Wednesday, September 14th. HSBC reaffirmed a hold rating and set a GBX 4,700 ($58.17) target price on shares of AstraZeneca plc in a research note on Thursday, August 11th. Beaufort Securities reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Wednesday, August 10th. Finally, Societe Generale set a GBX 7,000 ($86.63) target price on shares of AstraZeneca plc and gave the company a buy rating in a research note on Thursday, September 8th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. AstraZeneca plc presently has an average rating of Hold and a consensus price target of GBX 4,960.13 ($61.39).
AstraZeneca plc (LON:AZN) opened at 4950.50 on Tuesday. The stock’s market cap is GBX 62.62 billion. The company has a 50-day moving average price of GBX 4,998.32 and a 200 day moving average price of GBX 4,469.91. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.